Chris Boerner has served as Chief Executive Officer of Bristol Myers Squibb (BMS) since November 2023 and was elected Chair of the Board in April 2024. Having joined BMS in 2015, he rose through senior leadership roles culminating as Chief Commercialization Officer, where he oversaw the company’s global Commercial and Medical organizations. In that capacity, he played a central role in scaling BMS’s oncology and immunology franchises, strengthening global access strategies, and translating scientific innovation into broad clinical adoption across major markets.
As CEO, Boerner has prioritized sustaining BMS’s leadership in immuno-oncology and hematologic malignancies, reinforcing late-stage development and global patient access while maintaining a high bar for scientific and clinical differentiation. Before BMS, Boerner held senior roles at Genentech and Seattle Genetics, giving him deep exposure to oncology development and commercialization across different operating models. His background combines strategy, execution, and market access expertise, positioning him to lead BMS through its next phase as a company defined not by expansion alone, but by a durable impact in cancer care built on decades of immuno-oncology leadership.
The 100 CEOs featured here reflect the diversity and complexity of modern oncology leadership. In 2025, some lead the world’s largest cancer institutions; others guide specialized societies or emerging innovators. What unites them is responsibility: for millions of patients, for the integrity of science, and for the future direction of cancer care globally.
This list is not a celebration of power, but a recognition of stewardship, accountability, and impact – and of the leaders whose choices continue to shape the fight against cancer. For the many deserving individuals not mentioned in this list, we will continue to acknowledge, honor and elevate your voices in our daily publications from across the world.
See the full list of The 100 Most Influential CEOs in Oncology in 2025, and stay tuned for other special category nominations.
